Spero Therapeutics appoints Debra Jeske Zack as chief medical officer

Reuters2026/07/27 12:06

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Spero Therapeutics appointed Debra Jeske Zack as chief medical officer to lead clinical development strategy as it advances SP001 into clinical development.
Zack most recently served as chief medical officer at Exagen; previously held clinical leadership roles at Xencor and Novartis’ Biotherapeutics Development Unit.
At Amgen, she was global development lead for Enbrel; earlier spent 10 years as an associate professor at UCLA treating rheumatology patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270800PRIMZONEFULLFEED9788251) on July 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Spero Therapeutics appoints Debra Jeske Zack as chief medical officer

You may also like

Crypto prices